About this item:
491 Views | 478 Downloads
Author Notes:
Correspondence: Daniel A. Goldstein, MD, Mailing address: Winship Cancer Institute of Emory University, 1365C Clifton Rd NE, Suite C5010, Atlanta, GA, 30322, dgolds8@emory.edu, Fax: 404-778-3366, Telephone: 646-522-9582
Conflicts of interest: G, SZ, CB, EN declare no conflicts of interest
Subjects:
Research Funding:
Funding: NIH T32 Grant - T32CA160040-02
Keywords:
- Science & Technology
- Life Sciences & Biomedicine
- Oncology
- Chemotherapy
- Colorectal cancer
- Cost-effectiveness
- Incremental cost effectiveness ratio
- Value
- FLUOROURACIL DOSE ADJUSTMENT
- COST-EFFECTIVENESS ANALYSIS
- RANDOMIZED-TRIAL
- UNITED-STATES
- GLUCURONOSYLTRANSFERASE 1A1
- 2-STAGE HEPATECTOMY
- BOLUS FLUOROURACIL
- LIVER METASTASES
- 1ST-LINE THERAPY
- PHASE-III
Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies
Abstract:
To evaluate, from a US payer perspective, the cost-effectiveness of treatment strategies for metastatic colorectal cancer (mCRC), we performed a systematic review of published cost-effectiveness analyses. We identified 14 papers that fulfilled our search criteria and revealed varying levels of value among current treatment strategies. Older agents such as 5-fluorouracil, irinotecan, and oxaliplatin provide high-value treatments. More modern agents targeting the EGFR or VEGF pathways, such as bevacizumab, cetuximab, and panitumumab, do not appear to be cost-effective treatments at their current costs. The analytical methods used within the papers varied widely, and this variation likely plays a significant role in the heterogeneity in incremental cost-effectiveness ratios. The cost-effectiveness of current treatment strategies for mCRC is highly variable. Drugs recently approved by the US Food and Drug Administration for mCRC are not cost-effective, and this is primarily driven by high drug costs.
Copyright information:
© 2016 Elsevier Inc.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).
